Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. disclosed a new insider filing for director Eiry Roberts on a Form 3. This form establishes her status as a reporting person for the company’s securities. The filing does not list any stock or option transactions or provide current holdings.
Bausch Health Companies Inc. reported results of its Annual Meeting of Shareholders held on May 19, 2026. Shareholders elected all nominated directors, including new director Eiry W. Roberts, M.D., to serve until the 2027 annual meeting or earlier resignation or removal.
Shareholders also approved, on a non-binding advisory basis, the compensation of the Named Executive Officers as described in the company’s proxy materials. In addition, they appointed PricewaterhouseCoopers LLP as the independent registered public accounting firm through the 2027 annual meeting and authorized the board to set the auditors’ remuneration.
Bausch Health Companies Inc. reports first-quarter 2026 results showing a sharp swing to loss driven by a major goodwill write-down. Revenue reached $2,524 million, up from $2,259 million a year earlier, but operating performance was overshadowed by non-cash charges.
The company recorded a $1,426 million goodwill impairment in its Salix reporting unit after Phase 3 trial failures, leading to a net loss of $1,431 million versus a $86 million loss in 2025. Shareholders’ equity moved from positive $377 million at year-end 2025 to a deficit of $1,082 million, while long-term debt remained high at $20,212 million principal.
Bausch Health Companies Inc. reported strong Q1 2026 revenue growth but a large accounting loss driven by a goodwill charge. Consolidated revenue was $2.52 billion, up 12% year over year and 7% on an organic basis, led by 18% organic growth at Salix and 6% organic growth at Bausch + Lomb.
GAAP net loss attributable to Bausch Health was $1.423 billion, mainly from a $1.426 billion goodwill impairment tied to the Salix RED‑C program. On a non‑GAAP basis, adjusted net income attributable to Bausch Health rose to $296 million, with adjusted EPS of $0.78 versus $0.59 a year earlier and adjusted EBITDA attributable to Bausch Health of $837 million, up from $661 million.
The company generated $230 million of operating cash in the quarter and ended March 31, 2026 with $1.299 billion in cash and cash equivalents and $20.764 billion of total long‑term debt and other. Management reaffirmed 2026 guidance, targeting consolidated revenue of $10.67–$10.92 billion and adjusted EBITDA of $3.885–$4.010 billion, and highlighted ongoing Phase 3 development of larsucosterol for alcohol‑associated hepatitis.
Bausch Health Companies Inc. is soliciting shareholder votes for its 2026 virtual annual meeting on May 19, 2026 at 9:00 a.m. Eastern. Shareholders will elect ten directors for one-year terms, cast an advisory vote on 2025 executive compensation, appoint PricewaterhouseCoopers LLP as auditor through the 2027 meeting, and receive the audited 2025 financial statements.
The board is largely independent, with nine of ten nominees meeting independence standards, and board gender representation is expected to rise to 40% if all nominees are elected. The company details director share ownership guidelines, committee structure, risk oversight, and ESG priorities, including information security, carbon and energy initiatives, and employee health, safety and development.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation award in the form of Restricted Share Units for her board service for the quarter ending March 31, 2026. She acquired 5,946 common shares at a deemed price of $5.40 per share, bringing her direct holdings to 44,354 common shares.
Bausch Health Companies Inc. director John Paulson reported an equity compensation grant rather than an open-market trade. He acquired 11,574 common share equivalents at $5.40 per share as Restricted Share Units issued in lieu of cash fees for his board service for the quarter ending March 31, 2026.
After this award, he holds 371,694 common shares directly and has an additional 73,255,869 shares reported as indirectly owned by managed funds. A footnote states these securities are directly owned by the funds, and Paulson disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation award for Board service. She acquired 1,273 Restricted Share Units issued in lieu of cash compensation for the quarter ending March 31, 2026, each representing a contingent right to receive one common share. Following this grant, she directly holds 267,714 common shares, including the awarded units.